^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma

Published date:
11/06/2019
Excerpt:
Studies have combined daratumumab, a human IgGκ monoclonal antibody that targets CD38 which is highly expressed on myeloma cells, with proteasome inhibitors and immunomodulatory agents-based regimens in the first-line treatment of NDMM….Upfront combination regimen with daratumumab significantly improved PFS, ORR, sCR and CR along with negative MRD, compared to control arm in patients with NDMM.
Secondary therapy:
bortezomib + prednisone + dexamethasone + melphalan
DOI:
https://doi.org/10.1182/blood-2019-123131
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.

Excerpt:
...Rate (%) of CD38 expression and clonogenic potential of collected CD34+ cells in both groups.`...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

PRE-TREATMENT CD38 EXPRESSION LEVELS IN MYELOMA CELLS AND CD38-POSITIVE REGULATORY T CELLS AFFECT THE RESPONSE OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TO TREATMENT WITH DARATUMUMAB

Published date:
05/17/2018
Excerpt:
We included 28 relapsed/refractory myeloma patients, who were treated with DARA....We confirmed that pre-treatment levels of CD38 MFI were significantly higher in responders than in non-responders (p = 0.001).